Editorial: CCR5: A receptor at the center stage in infection
Front Immunol
.
2022 Oct 18:13:1054430.
doi: 10.3389/fimmu.2022.1054430.
eCollection 2022.
Authors
Joel Henrique Ellwanger
1
,
Massimiliano Secchi
2
,
Julio Aliberti
3
,
Luca Vangelista
4
Affiliations
1
Laboratory of Immunobiology and Immunogenetics, Department of Genetics, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.
2
Institute of Molecular Genetics, National Research Council, Pavia, Italy.
3
Office of AIDS Research, National Institutes of Health (NIH OAR), Bethesda, MD, United States.
4
Department of Biomedical Sciences, School of Medicine, Nazarbayev University, Astana, Kazakhstan.
PMID:
36330512
PMCID:
PMC9623291
DOI:
10.3389/fimmu.2022.1054430
No abstract available
Keywords:
CCR5; CCR5Δ32; COVID-19; HIV therapy; gene-editing; infection; leronlimab; maraviroc.
Publication types
Editorial
Research Support, Non-U.S. Gov't
MeSH terms
HIV-1*
Receptors, CCR5 / genetics
Substances
Receptors, CCR5